Searching for biomarkers in schizophrenia and psychosis: Case‐control study using capillary electrophoresis and liquid chromatography time‐of‐flight mass spectrometry and systematic review for biofluid metabolites. Issue 1 (8th December 2021)

• Record Type: Journal Article
• Authors: Kim, Saehyeon; Okazaki, Satoshi; Otsuka, Ikuo; Shinko, Yutaka; Horai, Tadasu; Shimmyo, Naofumi; Hirata, Takashi; Yamaki, Naruhisa; Tanifuji, Takaki; Boku, Shuken; Sora, Ichiro; Hishimoto, Akitoyo
• Is Part Of: Neuropsychopharmacology reports. Volume 42:Issue 1(2022)
• Page Start: 42
• Page End: 51
• Publication Date: 2021-12-08
• Subjects: biomarkers -- metabolomics -- psychosis -- schizophrenia -- systematic review; Neuropsychopharmacology -- Periodicals; 615.78
• DOI: 10.1002/npr2.12223
• Languages: English
• ISSNs: 2574-173X

Abstract

Abstract: Metabolomics has been attracting attention in recent years as an objective method for diagnosing schizophrenia. In this study, we analyzed 378 metabolites in the serum of schizophrenia patients using capillary electrophoresis‐ and liquid chromatography‐time‐of‐flight mass spectrometry. Using multivariate analysis with the orthogonal partial least squares method, we observed significantly higher levels of alanine, glutamate, lactic acid, ornithine, and serine and significantly lower levels of urea, in patients with chronic schizophrenia compared to healthy controls. Additionally, levels of fatty acids (15:0), (17:0), and (19:1), cis‐11‐eicosenoic acid, and thyroxine were significantly higher in patients with acute psychosis than in those in remission. Moreover, we conducted a systematic review of comprehensive metabolomics studies on schizophrenia over the last 20 years and observed consistent trends of increase in some metabolites such as glutamate and glucose, and decrease in citrate in schizophrenia patients across several studies. Hence, we provide substantial evidence for metabolic biomarkers in schizophrenia patients through our metabolomics study. Abstract : In this study, we analyzed 378 metabolites in the serum of schizophrenia patients using CE and LC‐TOFMS. With a systematic review, here we provide substantial evidence for metabolic biomarkers in schizophrenia patients through our metabolomics study.